Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23069532 | 0.92 | ALDH1A1 (0.54) | ALDH1A1MAPTCES2CES1LMNA | |
| SCHEMBL27814845 | 0.86 | MAPT (0.48) | ALDH1A1MAPTCES2CES1LMNA | |
| SCHEMBL183594 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPTCES2CES1LMNA | |
| SCHEMBL27537619 | 0.83 | MAPT (0.59) | ALDH1A1MAPTLMNAKDM4EDUSP3 | |
| SCHEMBL4933827 | 0.83 | MAPT (0.59) | ALDH1A1MAPTLMNAKDM4EDUSP3 | |
| SCHEMBL65558 | 0.83 | MAPT (0.59) | ALDH1A1MAPTLMNAKDM4EDUSP3 | |
| SCHEMBL1488916 | 0.83 | MAPT (0.59) | ALDH1A1MAPTLMNAKDM4EDUSP3 | |
| SCHEMBL165589 | 0.82 | NAAA (0.39) | ALDH1A1MAPTLMNAFFAR3NAAA | |
| SCHEMBL2555978 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MAPTCES2CES1LMNA | |
| SCHEMBL29090828 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MAPTCES2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912179-B2 | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-12-16 | — | — | US | disclosed |
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2611444-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029070-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
| EP-1311265-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6743812-B1 | 2,3-DIACYLTARTARIC ACID SALTS OF E-METANICOTINE; NERVOUS SYSTEM DISORDERS; AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES | TARGACEPT, INC. | 2004-06-01 | — | — | US | disclosed |
| EP-1317267-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | Targacept, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1311265-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | Targacept, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| US-5326782-A | Salts derived from 26-(dialkylaminoalkylsulphonyl)pristinamycin IIB | RHONE-POULENC RORER S.A. (FR) | 1994-07-05 | — | — | US | disclosed |
| CN-1017527-B | Process for preparing optically active oxoisoindolinyl derivatives | ERBA FARMITALIA (IT) | 1992-07-22 | — | — | CN | disclosed |
| WO-1992001694-A1 | NEW SALTS DERIVED FROM DIALKYLAMINOALKYLSULPHONYL-26 PRISTINAMYCIN II¿B? | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
| CN-88101200-A | The preparation method of the oxo-isoindolinyl derivatives of optically-active | — | 1988-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | HRH3, HRH4, HRH1 | ALDH1A1 1573/4885MAPT 1441/4885CES2 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.